This Managing Survivorship session was titled Treatment Options Update for Patients Newly Diagnosed or with Recurrent Prostate Cancer. The speakers included PHEN Director of Clinical Trials and Patient Education, Dr. Keith Crawford, and PHEN Senior Scientific Research Analyst, Dr. David Vasir.
The speakers presented details regarding NCCN prostate cancer screening updates, treatment options, and clinical trials.
“Clinical trials are part of your treatment options. That’s why we incorporate them,” explained Dr. Crawford.
Dr. Crawford shared the PHENPath.com website with the audience, describing the treatment options based on five common prostate cancer diagnoses. These diagnoses are:
- Initial prostate cancer diagnosis before treatment
- PSA recurrence after surgery
- Cancer progression after radiation
- Advanced hormone sensitive cancer
- Castration-resistant cancer
Dr. David Vasir highlighted the Life Expectancy Table on PHENPath.com and discussed NCCN prostate cancer screening guidelines. Early detection improves treatment success, with MRIs now advised before biopsies and PSMA-PET scans for assessing spread. Testing after age 75 depends on overall health. Black men and those at high risk should start screening at age 40.
The webinar covered new treatments for advanced hormone-sensitive and hormone-resistant prostate cancer, highlighting androgen deprivation therapy drugs like abiraterone, enzalutamide, darolutamide, leuprolide, and relugolix. Chemotherapy options such as docetaxel and cabazitaxel were also discussed. Recent updates in screenings and therapies allow care plans tailored to individual genetics and scans.
Dr. Crawford additionally addressed the ARASTEP clinical trials, which are sponsored by the biopharmaceutical company Bayer. This ongoing Phase 3 trial is evaluating the effects of darolutamide combined with ADT compared to placebo and ADT on the progression of prostate cancer.